EUCTR2005-005362-36-IT进行中（未招募）不适用
A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS MTOR-INHIBITOR-FREE IMMUNOSUPPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA - SILVER
REGENSBURG UNIVERSITY MEDICAL CENTRE0 个研究点目标入组 525 人开始时间: 2007年2月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 525
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age 18 years 2. Histologically proven HCC before randomisation 3. Signed, written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Multiple-organ recipients 2. Known hypersensitivity to sirolimus or its derivates 3. Hyperlidemia refractory to optimal medical management 4. Evidence of significant local or systemic infection 5. Known HIV-positive patients 6. Platelets 75.000/cubic mm 7. Women of child-bearing potential not willing to take contraception 8. Patients with non-HCC malignancies within the past 5 years excluding successfully treated squamous cell carcinoma and basal cell carcinoma of the skin
研究者
相似试验
进行中（未招募）
不适用
A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA - SiLVERProphylaxis against liver transplant rejection in patients undergoing liver transplantation for hepatocellular carcinoma (HCC)MedDRA version: 8.1Level: LLTClassification code 10050434EUCTR2005-005362-36-ATRegensburg University Hospital482
进行中（未招募）
不适用
A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA - SiLVERProphylaxis against liver transplant rejection in patients undergoing liver transplantation for hepatocellular carcinoma (HCC)MedDRA version: 8.1Level: LLTClassification code 10050434EUCTR2005-005362-36-SERegensburg University Hospital482
进行中（未招募）
不适用
A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA - SiLVERProphylaxis against liver transplant rejection in patients undergoing liver transplantation for hepatocellular carcinoma (HCC)MedDRA version: 8.1Level: LLTClassification code 10050434EUCTR2005-005362-36-GBRegensburg University Hospital482
进行中（未招募）
不适用
A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA - SiLVERProphylaxis against liver transplant rejection in patients undergoing liver transplantation for hepatocellular carcinoma (HCC)MedDRA version: 8.1Level: LLTClassification code 10050434EUCTR2005-005362-36-FIRegensburg University Hospital482
进行中（未招募）
1 期
A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA - SiLVERProphylaxis against liver transplant rejection in patients undergoing liver transplantation for hepatocellular carcinoma (HCC)MedDRA version: 8.1Level: LLTClassification code 10050434EUCTR2005-005362-36-NORegensburg University Hospital482